首页> 外文期刊>Contraception >Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
【24h】

Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.

机译:屈螺酮3 mg +乙炔雌二醇20 mcg 24/4联合口服避孕药的出血模式与去氧孕烯150 mcg +乙炔雌二醇20 mcg 21/7联合口服避孕药的出血模式。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The study was conducted to compare cycle control, bleeding pattern and efficacy of two low-dose combined oral contraceptives. STUDY DESIGN: Four hundred fifty-three women were randomized to receive a 24/4 regimen of drospirenone 3 mg/ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg; n=230) or a 21/7 regimen of desogestrel 150 mcg/EE 20 mcg (DSG 150 mcg/EE 20 mcg; n=223), and recorded bleeding daily over 7 treatment cycles. RESULTS: The duration [mean 4.7 (SD 1.5)-5.2 (SD 2.2) days in the drsp 3 mg/EE 20 mcg 24/4 group and 5.1 (SD 1.5)-5.4 (SD 2.1) days in the DSG 150 mcg/ EE 20 mcg group] and maximum intensity ("normal bleeding" for >50% of all subjects) of scheduled bleeding in Cycles 1-6 was comparable between treatment groups. The incidence of unscheduled bleeding during Cycles 2-6 was also similar between the two groups (drsp 3 mg/EE 20 mcg, 8.8-17.3%; DSG 150 mcg/ EE 20 mcg, 9.4-16.3%). CONCLUSION: Drsp 3 mg/EE 20 mcg 24/4 achieved an acceptable bleeding profile with reliable cycle control, comparable with an established formulation.
机译:背景:本研究旨在比较两种低剂量联合口服避孕药的周期控制,出血模式和疗效。研究设计:453名女性被随机分配接受24/4方案的屈螺酮3 mg /乙炔雌二醇20 mcg(drsp 3 mg / EE 20 mcg; n = 230)或地索孕酮150 mcg的21/7方案/ EE 20 mcg(DSG 150 mcg / EE 20 mcg; n = 223),并在7个治疗周期内每天记录出血。结果:持续时间[在drsp 3 mg / EE 20 mcg 24/4组中分别为4.7(SD 1.5)-5.2(SD 2.2)天,在DSG 150 mcg /中分别为5.1(SD 1.5)-5.4(SD 2.1)天。 EE 20 mcg组]和1-6周期计划出血的最大强度(“正常出血”占所有受试者的50%以上)在治疗组之间是可比的。两组之间第2-6周期的计划外出血发生率也相似(drsp 3 mg / EE 20 mcg,8.8-17.3%; DSG 150 mcg / EE 20 mcg,9.4-16.3%)。结论:Drsp 3 mg / EE 20 mcg 24/4达到了可接受的出血特征,具有可靠的周期控制,与既定的制剂相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号